$39.75
Apellis Pharmaceuticals is a biotechnology business based in the US. Apellis Pharmaceuticals shares (APLS) are listed on the NASDAQ and all prices are listed in US Dollars. Apellis Pharmaceuticals employs 702 staff and has a trailing 12-month revenue of around $524.1 million.
Our top picks for where to buy Apellis Pharmaceuticals stock
How to buy Apellis Pharmaceuticals stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – APLS. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Apellis Pharmaceuticals stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Apellis Pharmaceuticals stock price (NASDAQ: APLS)
Use our graph to track the performance of APLS stocks over time.Apellis Pharmaceuticals shares at a glance
Latest market close | $38.88 |
---|---|
52-week range | $19.83 - $73.80 |
50-day moving average | $40.18 |
200-day moving average | $52.15 |
Wall St. target price | $74.94 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-3.43 |
Is it a good time to buy Apellis Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Apellis Pharmaceuticals price performance over time
Historical closes compared with the close of $38.88 from 2024-07-25
1 week (2024-07-19) | 2.37% |
---|---|
1 month (2024-06-27) | -6.36% |
3 months (2024-04-26) | -22.02% |
6 months (2024-01-26) | -39.29% |
1 year (2023-07-27) | 21.08% |
---|---|
2 years (2022-07-27) | -32.26% |
3 years (2021-07-27) | 65.59 |
5 years (2019-07-26) | 35.19% |
Apellis Pharmaceuticals financials
Revenue TTM | $524.1 million |
---|---|
Gross profit TTM | $69.8 million |
Return on assets TTM | -27.9% |
Return on equity TTM | -122.94% |
Profit margin | -79.62% |
Book value | $2.20 |
Market Capitalization | $4.6 billion |
TTM: trailing 12 months
Apellis Pharmaceuticals share dividends
We're not expecting Apellis Pharmaceuticals to pay a dividend over the next 12 months.
Apellis Pharmaceuticals share price volatility
Over the last 12 months, Apellis Pharmaceuticals's shares have ranged in value from as little as $19.8301 up to $73.8. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Apellis Pharmaceuticals's is 0.873. This would suggest that Apellis Pharmaceuticals's shares are less volatile than average (for this exchange).
Apellis Pharmaceuticals overview
Apellis Pharmaceuticals, Inc. , a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
Frequently asked questions
nullWhat percentage of Apellis Pharmaceuticals is owned by insiders or institutions?
Currently 14.324% of Apellis Pharmaceuticals shares are held by insiders and 94.473% by institutions. How many people work for Apellis Pharmaceuticals?
Latest data suggests 702 work at Apellis Pharmaceuticals. When does the fiscal year end for Apellis Pharmaceuticals?
Apellis Pharmaceuticals's fiscal year ends in December. Where is Apellis Pharmaceuticals based?
Apellis Pharmaceuticals's address is: 100 Fifth Avenue, Waltham, MA, United States, 02451 What is Apellis Pharmaceuticals's ISIN number?
Apellis Pharmaceuticals's international securities identification number is: US03753U1060 What is Apellis Pharmaceuticals's CUSIP number?
Apellis Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 03753U106
More guides on Finder
-
Opto review 2024: $0 commission, fractional theme investing
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
-
Best paper trading platforms to practice trading with fake money [2024]
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
-
How to buy the new spot Ethereum ETFs
Spot Ethereum ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
-
Best broker cash sweep rates for July 2024
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
7 best day trading platforms of July 2024
These are the best day trading platforms, according to Finder’s comprehensive analysis.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
10 top semiconductor stocks to buy in 2024
We’ve rounded up stats on some of the most popular semiconductor stocks, along with information on how they compare and how to invest.
-
11 best brokerage accounts of July 2024: Top picks for investors
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
7 best ways to invest $10K
Check out our 7 ideas for how to invest $10K to maximize your money.
Ask a question